| Title |
Von Hippel-Lindau syndrome: molecular mechanisms of the disease
|
|---|---|
| Published in |
Clinical and Translational Oncology, March 2010
|
| DOI | 10.1007/s12094-010-0485-9 |
| Pubmed ID | |
| Authors |
María J. Calzada |
| Abstract |
Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene is responsible for the development of renal carcinomas, pheochromocytomas and tumours in other organs. The gene product (pVHL) is a central component in the oxygen-sensing pathway through its role in the regulation of the hypoxia-inducible factor (HIF). Loss of pVHL leads to activation of the HIF pathway in normoxia with the concomitant increase in tumour vascularisation due to the up-regulation of pro-angiogenic genes. However, although the role of pVHL in the regulation of HIF has proved to be important for tumour growth, other pVHL functions independent of HIF have been reported and help to explain why loss of VHL leads to renal cancer. Studies aimed to characterise other molecular pathways that shed light on its physiological roles as a gatekeeper gene in kidney and other organs will be very helpful for the development of novel anticancer therapies. |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 7 | 21% |
| Student > Ph. D. Student | 5 | 15% |
| Other | 3 | 9% |
| Researcher | 3 | 9% |
| Student > Postgraduate | 3 | 9% |
| Other | 7 | 21% |
| Unknown | 6 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 10 | 29% |
| Medicine and Dentistry | 10 | 29% |
| Agricultural and Biological Sciences | 6 | 18% |
| Psychology | 1 | 3% |
| Neuroscience | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 5 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2023.
All research outputs
#8,352,910
of 24,969,131 outputs
Outputs from Clinical and Translational Oncology
#409
of 1,440 outputs
Outputs of similar age
#37,294
of 101,015 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 6 outputs
Altmetric has tracked 24,969,131 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,440 research outputs from this source. They receive a mean Attention Score of 4.0. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,015 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them